🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the battle against superbug strains of the infection, according to scientists.

A Global Health Concern

Cases of gonorrhoea are on the rise around the world, with figures suggesting in excess of 82 million instances each year. Especially elevated rates are seen in the African continent and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the reality of rising global incidence, escalating drug resistance and the very limited available drugs currently available.”

Public health authorities are deeply concerned about the surge in drug-resistant strains. The WHO has classified it as a "high-priority threat". A tracking program found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Secure Clearance

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in December for combating gonorrhoea. This STI can lead to major issues, including infertility. Experts hope that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, was also approved in the same week. This medication, which is also used to treat urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to develop it.

“This milestone signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Data and Worldwide Availability

As per findings published in a major medical journal, zoliflodacin cured the vast majority of cases of the STI. This puts it on an comparable level with the typical regimen, which combines two antibiotics. The trial involved nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the ability to make available and distribute the drug in numerous regions with limited resources.

Clinicians treating patients have expressed hope. Having a one-pill regimen such as this is seen as a "revolutionary step" for public health efforts. This is viewed as essential to lessen the impact of the illness for people and to prevent the spread of highly drug-resistant gonorrhoea globally.